Key Takeaways:
- ENT UK 2024 guidance formally acknowledges microsuction noise as a clinical risk, placing responsibility on practitioners to minimise patient exposure
- Traditional devices record 118.3 dB overall with peaks of 150.6 dB; Zephyr achieves 93.4 dB overall (8x quieter) with peaks of 129.7 dB
- Informed consent must now explicitly address acoustic risks, including potential tinnitus and hearing changes
- If your device manufacturer cannot provide independent acoustic testing data, that itself is a compliance concern under the new guidance
What the ENT UK 2024 Guidance Says
ENT UK — the professional body representing ear, nose, and throat specialists across the United Kingdom — updated its guidance on microsuction in 2024 to address growing concerns around noise-induced harm during ear wax removal procedures.
The guidance formally acknowledges that microsuction devices generate noise levels capable of causing acoustic trauma, and it places responsibility on practitioners to take reasonable steps to minimise patient exposure. While the guidance stops short of mandating specific equipment, it establishes a clear expectation: clinicians should understand the noise profile of their devices and actively work to reduce acoustic risk.
With approximately 4 million ear wax removal procedures performed in the UK each year, the implications are significant for every practice offering microsuction — from NHS audiology departments to independent high street clinics.
Key Areas the Guidance Addresses
Noise Exposure During Procedures
The guidance recognises that traditional microsuction equipment can produce noise levels exceeding 115 dB within the ear canal. Independent testing data supports this, with conventional devices recording an overall Laeq of 118.3 dB and peak levels (Cpeak) averaging 150.6 dB across typical procedures.
These figures place patients in a noise environment comparable to industrial settings where hearing protection is legally required — yet the noise source is positioned directly at the entrance to the ear canal.
Informed Consent
The updated guidance strengthens the expectation around informed consent. Practitioners should ensure patients understand the potential acoustic risks of microsuction, including the possibility of temporary or permanent hearing changes and tinnitus. This is particularly relevant for patients with pre-existing hearing conditions.
Equipment Selection
While the guidance does not endorse specific products, it makes clear that equipment choice is a component of safe practice. Practitioners are expected to consider the noise output of their devices and, where possible, select equipment that minimises acoustic exposure.
Documentation and Clinical Governance
The guidance reinforces the importance of documenting equipment specifications, maintenance schedules, and any adverse events. Practices should be able to demonstrate that their equipment choices reflect current best practice in acoustic safety.
What This Means for Your Equipment Choices
The Compliance Question
The central question for any practice is straightforward: does your current microsuction equipment align with the ENT UK 2024 guidance on acoustic safety?
To answer this, you need acoustic data for your device. Specifically:
| Measurement | What It Tells You | What to Look For |
|---|---|---|
| Laeq (overall) | Average noise exposure across a procedure | Below 95 dB ideally; traditional devices average 118.3 dB |
| Startup noise | Initial noise burst when device activates | Below 70 dB; traditional devices hit 108.5 dB |
| Active suction (Phase 3) | Noise during actual wax removal | Below 100 dB; traditional devices reach 119.0 dB |
| Cpeak | Maximum transient noise spikes | Below 135 dB; traditional devices average 150.6 dB |
If your device manufacturer cannot provide independent acoustic testing data, that itself is a concern under the new guidance framework.
How Zephyr Meets the Standard
The Spoke Medical Zephyr was designed with acoustic safety as a primary engineering objective — and its performance data directly addresses every metric the ENT UK guidance highlights.
Zephyr is ENT UK 2024 Compliant and delivers:
- Overall noise (Laeq): 93.4 dB vs 118.3 dB for traditional devices — 24.9 dB quieter, approximately 8x lower sound pressure level
- Startup noise: 65.0 dB vs 108.5 dB — effectively silent at startup, 43.5 dB quieter
- Active suction: 95.2 dB vs 119.0 dB — 23.8 dB quieter during the working phase
- Peak levels (Cpeak): 129.7 dB average vs 150.6 dB — substantially below the threshold of concern
These figures come from independent testing across 30 procedures, measured at 1/32-second precision across all three operational phases (startup, idle, active suction). The device operates at 75 dB or below during routine use.
Steps to Ensure Your Practice is Compliant
1. Audit Your Current Equipment
Document the make, model, and age of every microsuction device in use. Request acoustic performance data from the manufacturer. If none is available, consider commissioning independent testing or replacing the device.
2. Review Your Consent Process
Ensure your consent forms and verbal explanations cover the acoustic risks of microsuction. Consider whether different consent language is needed for higher-risk patients — those with existing hearing loss, tinnitus, or hyperacusis.
3. Evaluate Replacement Options
If your current equipment cannot demonstrate compliance with the spirit of the ENT UK guidance, replacement should be a priority. When evaluating alternatives, prioritise devices with:
- Independent, published acoustic testing data
- Regulatory approval
- Explicit ENT UK 2024 compliance claims
- Patented noise reduction technology (not just marketing claims)
4. Update Your Clinical Governance Framework
Incorporate equipment noise specifications into your clinical governance documentation. Record the acoustic rationale for equipment selection and maintain a log of any noise-related patient complaints or adverse events.
5. Train Your Team
Ensure all practitioners understand the guidance, can articulate the acoustic risks to patients, and know how to operate equipment in ways that minimise unnecessary noise exposure — for example, avoiding unnecessary activation of suction before positioning in the ear canal.
The Broader Trajectory
The ENT UK 2024 guidance reflects a broader trend in clinical practice: the expectation that practitioners will proactively manage risks that were previously considered acceptable or unavoidable. Noise exposure during microsuction falls squarely into this category.
For practices that act now, the benefits extend beyond compliance. Lower noise means fewer adverse events, better patient experiences, reduced litigation risk, and a demonstrable commitment to clinical excellence. The guidance has made the case — the equipment you choose is how you respond to it.